



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Professor Otmar D. Wiestler appointed to the Supervisory Board of Bayer AG

Dr. Klaus Kleinfeld concentrating on other offices and honorary posts, some in the USA

Leverkusen, Germany, October 8, 2014 – The Local Court of Cologne has appointed Professor Otmar D. Wiestler (57) to the Supervisory Board of Bayer AG. He replaces Dr. Klaus Kleinfeld (56), who left the Supervisory Board at his own request effective September 30, 2014, in order to concentrate on his other offices and honorary posts, some of which are in the United States. "We would like to thank Mr. Kleinfeld for our very successful and trusting cooperation. In Professor Wiestler we have found a competent successor with extensive scientific expertise," said Werner Wenning, Chairman of the Supervisory Board of Bayer AG.

Since January 1, 2004, Wiestler has been Chairman of the Management Board and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Also since 2004 he has been Chairman of the Advisory Committee and a member of the board of German Cancer Aid. From 2007 to 2012, he was a Vice-President in the Executive Committee of the Helmholtz Association.

Kleinfeld has been Chief Executive Officer of U.S. metals and technology company Alcoa Inc. since May 2008. He joined the Supervisory Board of Bayer AG on April 29, 2005.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate

citizen. In fiscal 2013, the Group employed 113,200 people and had sales of EUR 40.2 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 3.2 billion. For more information, go to www.bayer.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Jürgen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Judith Nestmann (+49-214-30-66836)

Constance Spitzer (+49-214-30-33021)

Dr. Olaf Weber (+49-214-30-33567)

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.